ERBB2 and breast cancer: The first recommendation stated, “Don’t routinely use sentinel node biopsy in clinically node-negative women ≥70 years of age with early-stage HR-positive, HER2-negative invasive breast cancer”.1 This recommendation was based on several prospective trials highlighting that SLNB had no impact on locoregional recurrence or breast cancer-specific mortality in this group of patients.6–9